Skip to main content

Table 2 Clinicopathological characteristics according to HER2 protein expression status

From: Relationship between HER2 overexpression and long-term outcomes of early gastric cancer: a prospective observational study with a 6-year follow-up

Item HER2 negative
N = 181
HER2 overexpression
N = 30
P value
Age (year, Mean ± SD) 61.4 ± 9.7 62.3 ± 10.3 0.737
Sex (Male, %) 138 (76.2) 24 (80.0) 0.652
Tumor location (n/%)a    0.033
Upper 1/3 49 (27.1) 14 (46.7)  
Middle 1/3 26 (14.4) 6 (20.0)  
Lower 1/3 106 (58.6) 10 (33.3)  
Gross type (n/%)    0.183
Elevated 79 (43.6) 14 (46.7)  
Flat 58 (32.0) 13 (43.3)  
Depressed 44 (24.3) 3 (6.4)  
Depth of invasion (n/%) a    0.147
Mucous layer 168 (92.8) 25 (83.3)  
Submucosa 13 (7.2) 5 (16.7)  
Differentiated types (n/%)a    0.371
Differentiated 170 (93.9) 30 (100.0)  
Undifferentiated 11 (6.1) 0 (0.0)  
Tumor size (n/%) a    0.775
 ≤ 2 cm 155 (85.6) 27 (90.0)  
 > 2 cm 26 (14.4) 3 (10.0)  
Lymphovascular infiltration (n/%)a    0.461
Present 3 (1.7) 1 (3.3)  
Absent 178 (98.3) 29 (96.7)  
Resection margin (n/%)a    1.000
Positive 6 (3.3) 1 (3.3)  
Negative 175 (96.7) 29 (96.7)  
Current gastric ulcera 26 (14.4) 4 (13.3) 1.000
Current HP infectiona 24 (13.3) 2 (6.7) 0.547
  1. aTested by Fisher exact test